
The Use of Biosimilars in Hematology/Oncology Practice

References

1. US Food and Drug Administration. Biosimilars. Accessed February 15, 2022. <https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars>.
2. Cancer biologics Global Market Report 2021: COVID-19 Growth and Change to 2030. Accessed February 15, 2022. <https://www.researchandmarkets.com/reports/5446217/cancer-biologics-global-market-report-2021-covid>.
3. Hernandez I, Bott SW, Patel AS, et al. Pricing of monoclonal antibody therapies: higher if used for cancer? *Am J Manag Care*. 2018;24(2):109-112.
4. Botteri E, Krendyukov A, Curigliano G. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. *Eur J Cancer*. 2018;89:49-55. doi:10.1016/j.ejca.2017.10.034
5. Generics and Biosimilar Initiative (GABI). The sluggish US biosimilars market. Accessed February 15, 2022. <https://www.gabionline.net/reports/The-sluggish-US-biosimilars-market>.
6. Bennett CL, Nagai S, Bennett AC, et al. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions. *The Oncologist*. 2021;26(8):e1418-e1426. doi:10.1002/onco.13713
7. Whalen J. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies. *Am J Manag Care*. 2020;26(2 Suppl):S23-S31. doi:10.37765/ajmc.2020.42899
8. Chambers JD, Lai RC, Margaretos NM, Panzer AD, Cohen JT, Neumann PJ. Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. *JAMA*. 2020;323(19):1972-1973. doi:10.1001/jama.2020.2229
9. Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? *Front Pharmacol*. 2019;10:279. doi:10.3389/fphar.2019.00279

Provided by MediCom Worldwide, Inc.

This activity is supported by an educational grant from Pfizer, Inc.